Drug intelligence / Profile preview

doxorubicin + cyclophosphamide + nivolumab

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination involves **doxorubicin**, an anthracycline antibiotic that intercalates DNA strands, inhibiting macromolecular biosynthesis; **cyclophosphamide**, an alkylating agent that interferes with DNA replication; and **nivolumab**, a monoclonal antibody that blocks the PD-1 receptor, enhancing immune responses against cancer cells. The combination is explored for its potential to induce immunogenic cell death and enhance anti-tumor immune responses.

Brand names: OpdivoAdriamycin
Other names: Nivolumab + CANivolumab + Cyclophosphamide + Doxorubicin induction therapy

Targets

PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on doxorubicin + cyclophosphamide + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + cyclophosphamide + nivolumab.

Explore the full profile